This study, covering the period from 2000–14, shows that iatrogenic CJD due to cadaver-sourced pituitary growth hormone, a treatment that was discontinued in 1985 in the UK, continues to occur in the UK at a frequency of 0–6 cases per annum. This evidence concerns the gene GH1 and Creutzfeldt Jacob disease.